Source: Eur Respir J 2016; 48: 320-330
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Pascoe Steven J., Lipson David A., Locantore Nicholas, Barnacle Helen, Brealey Noushin, Mohindra Rajat, Dransfield Mark T., Pavord Ian, Barnes Neil. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J 2016; 48: 320-330

Member's Comments

No comment yet.

Related content which might interest you: RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017 Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Resistance arm training in patients with COPD: A randomized controlled trial Source: Annual Congress 2010 - Exercise training and pulmonary rehabilitation Year: 2010 Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? Source: ERJ Open Res 2016: 00055-2016 Year: 2016 Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021 ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016 Year: 2017 A self-management programme for COPD: a randomised controlled trial Source: Eur Respir J 2014; 44: 1538-1547 Year: 2014 Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Helium-hyperoxia a novel treatment for optimizing pulmonary rehabilitation: a randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 327s Year: 2007 Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010 Paclitaxel/carboplatin vs paclitaxel/carboplatin/etoposide as first line treatment in SCLC. A phase III randomized trial Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019 Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study Source: ERJ Open Res, 7 (1) 00077-2021; 10.1183/23120541.00077-2021 Year: 2021 A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007